17 September 2021
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
The Company announces that on 16 September 2021 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive Plan:
| Name of individual | Director | Type of award | Number of shares subject to award |
| Ian Page | Director | LTIP Award - nil cost option | 23,727 |
| Paul Sandland* | Director | LTIP Award - nil cost option | 11,000 |
| Tony Griffin | Director | LTIP Award - conditional award | 6,508 |
* Paul Sandland has also been granted a tax qualifying option over 330 shares at an exercise price of £49.09 as part of his LTIP award. This tax qualifying option is linked to the nil cost option such that, at the time of exercise, to the extent that there is a gain in the tax qualifying option, the nil cost option will be forfeited to the value of that gain.
The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Ian Page
| ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Director
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Dechra Pharmaceuticals PLC | ||||
| b) | LEI code | 213800J4UVB5OWG8VX82 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | ||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan | ||||
| c) | Price(s) and volumes(s) | Nil cost option
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
N/A
N/A
| ||||
| e) | Date of the transaction | 2021-09-16 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Paul Sandland
| ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Director
| ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Dechra Pharmaceuticals PLC | ||||||||
| b) | LEI code | 213800J4UVB5OWG8VX82 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | ||||||||
| b) | Nature of the transaction | Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan | ||||||||
| c) | Price(s) and volumes(s) | Nil cost option
Tax qualifying option
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 11,330 Ordinary Shares in total
N/A | ||||||||
| e) | Date of the transaction | 2021-09-16 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Tony Griffin
| ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Director
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Dechra Pharmaceuticals PLC | ||||
| b) | LEI code | 213800J4UVB5OWG8VX82 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | ||||
| b) | Nature of the transaction | Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan | ||||
| c) | Price(s) and volumes(s) | Conditional award
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
N/A
N/A
| ||||
| e) | Date of the transaction | 2021-09-16 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
